UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1227-10
Program Prior Authorization/Notification
Medication Benlysta® (belimumab)*
*This program applies to the subcutaneous formulation of belimumab
P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021, 4/2022, 7/2022,
7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment
of patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are
receiving standard therapy and in patients aged 5 years and older with active lupus nephritis
who are receiving standard therapy.
Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe
active central nervous system lupus. Use of Benlysta is not recommended in this situation.
2. Coverage Criteriaa:
A. Systemic Lupus Erythematosus
1. Initial Authorization
a. Benlysta will be approved based on all of the following criteria:
(1) Diagnosis of systemic lupus erythematosus
-AND-
(2) Patient is currently receiving standard immunosuppressive therapy [e.g.,
hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate]
-AND-
(3) Patient does not have severe active central nervous system lupus
-AND-
(4) Patient is not receiving Benlysta in combination with any of the following:
(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira
(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
(b) Lupkynis (voclosporin)
(c) Saphnelo (anifrolumab-fnia)
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
2. Reauthorization
a. Benlysta will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Benlysta therapy
-AND-
(2) Patient is not receiving Benlysta in combination with any of the following:
(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira
(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
(b) Lupkynis (voclosporin)
(c) Saphnelo (anifrolumab-fnia)
Authorization will be issued for 12 months.
B. Active Lupus Nephritis
1. Initial Authorization
a. Benlysta will be approved based on all of the following criteria:
(1) Diagnosis of active lupus nephritis
-AND-
(2) Patient is currently receiving standard immunosuppressive therapy for systemic
lupus erythematosus [e.g., hydroxychloroquine, chloroquine, prednisone,
azathioprine, methotrexate]
-AND-
(3) Patient does not have severe active central nervous system lupus
-AND-
(4) Patient is not receiving Benlysta in combination with any of the following:
(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira
(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
(b) Lupkynis (voclosporin)
(c) Saphnelo (anifrolumab-fnia)
Authorization will be issued for 12 months.
2. Reauthorization
a. Benlysta will be approved based on both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
2
(1) Documentation of positive clinical response to Benlysta therapy
-AND-
(2) Patient is not receiving Benlysta in combination with any of the following:
(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira
(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
(b) Lupkynis (voclosporin)
(c) Saphnelo (anifrolumab-fnia)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• The intravenous infusion is typically covered under the medical benefit. Please refer to the
UnitedHealthcare Drug Policy for Benlysta.
4. References:
1. Benlysta [package insert]. Durham, NC: GlaxoSmithKline; May 2024.
Program Prior Authorization/Notification - Benlysta (belimumab)
Change Control
9/2017 New program.
9/2018 Annual review with no changes to coverage criteria. Updated
reference.
9/2019 Annual review with no changes to coverage criteria. Updated
background to align with updated FDA label. Updated reference.
Added general NCCN recommended review criteria.
9/2020 Annual review. Updated reauthorization duration. Removed NCCN
recommended review criteria. Updated reference.
2/2021 Off cycle review. Background and clinical criteria updated to align
with updated FDA label for new indication for adult patients with active
lupus nephritis who are receiving standard therapy. References
updated.
7/2021 Added not to be used in combination with Lupkynis to criteria.
4/2022 Added not to be used in combination with Saphnelo (anifrolumab-fnia)
to criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
3
7/2022 Annual review with no changes to coverage criteria. Added state
mandate disclaimer.
7/2023 Annual review. Updated background. Updated coverage criteria for
SLE removing documentation of the presence of antibodies. Updated
not used in combination from biologic DMARD to targeted
immunomodulator without change in clinical intent. Updated reference.
7/2024 Annual review with no changes to coverage criteria. Updated
reference.
© 2024 UnitedHealthcare Services, Inc.
4